Amid continued uncertainty, healthcare and life sciences (HCLS) M&A appetite remains strong with a divergence in deal-making expectations. Nearly three quarters of life sciences respondents expect to increase their deal activity compared to 61% of healthcare, according to new findings from the 2026 KPMG Healthcare and Life Sciences Investment Outlook. The top factor likely to impact deal activity in 2026 reported by respondents is high valuations followed by uncertainties surrounding future performance and growth ability of targets, as well as competition for a limited number of high-value or innovative targets.
Read the full article: M&A Appetite Remains Robust Among Healthcare and Life Sciences Investors: KPMG Survey //
Source: https://kpmg.com/us/en/media/news/2026-hcls-investment-outlook.html